Agios Pharmaceuticals Q3 EPS $(1.64) Beats $(1.70) Estimate, Sales $7.40M Miss $7.52M Estimate
Portfolio Pulse from Benzinga Newsdesk
Agios Pharmaceuticals reported Q3 earnings per share (EPS) of $(1.64), beating the estimate of $(1.70) by 3.53%. However, the company's sales of $7.40M missed the estimate of $7.52M by 1.61%. The EPS is a 10.07% decrease from last year, while sales increased by 110.44% from the same period last year.
November 02, 2023 | 11:08 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Agios Pharmaceuticals' Q3 EPS beat estimates but sales missed. This mixed result could lead to uncertain short-term price movements.
Agios Pharmaceuticals' Q3 results were mixed, with EPS beating estimates but sales missing. This could lead to uncertainty in the market, potentially causing short-term price volatility.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100